TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07029945: A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Sponsor: Biojiva LLC · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 152 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,693,200

Rescue Site Savings

+$1,128,800

Unlock Full NCT07029945 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07029945 Rescue Dossier →